MedTrace Logo

Eplerenone Versus PDT: Comparative Study by OCTA

NCT05104138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-11-02

No results posted yet for this study

Summary

The study aims to analyze the changes in OCTA parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

Eplerenone

The patients underwent eplerenone treatment for 6 months

DEVICE

The patients underwent half fluence photodynamic therapy for 6 months

Half fluence photodynamic therapy for 6 months

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Gilda Cennamo · Università Federico II

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2017-10-30
Completion
2017-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104138 on ClinicalTrials.gov